RxDoctor Payments Data

Shawn Puri, MD

Interventional Pain Medicine · Killeen, TXNPI 1598056293

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $23,588 of the $36,800 with a category attached, or 64.1%. 34 manufacturers reported payments, led by Abbott at 38.1% of the total. Reporting peaked in 2023 at $11,146 and has fallen 79.9% since, to $2,237 in 2025.

$36,800in general payments, 2019–2025

Across 735 payments — averaging $50.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$14K
  • Vertos Medical, Inc.$6K
  • Omnia Medical, LLC$5K
  • Nevro Corp.$2K
  • SPR Therapeutics, Inc$2K
  • Spinal Simplicity, LLC$1K
  • plus $7K from 28 others

What the payments were for

  • Consulting fees$9,90027%
  • Speaking & faculty fees$840%
  • Travel & lodging$3,2009%
  • Food & beverage$23,58864%
  • Education$180%
  • Gifts$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,800 in reported general payments places this provider in the 85th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$214,295
Medicare patients
511
Services billed
3,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl61$44,755
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen783$17,947
Xtampza ErOxycodone Myristate22$9,392
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen246$6,125
LinzessLinaclotide11$5,319
Buprenorphine17$3,179
Lidocaine36$3,178
Gabapentin223$2,820
Pregabalin119$2,458
Tramadol Hcl ErTramadol Hcl22$1,493
Tramadol Hcl213$1,332
Tizanidine Hcl179$1,310
Morphine Sulfate ErMorphine Sulfate69$1,274
Oxycodone Hcl79$812
Duloxetine Hcl41$769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$156$54,14783 claims
AbbVieLinzess$16$5,31911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Killeen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →